The palivizumab patchwork: Variation in guidelines for Respiratory Syncytial Virus prevention across Canadian provinces and territories

Abstract

Abstract Background Respiratory Syncytial Virus is the leading cause of hospitalization for lower respiratory tract infection in young children. The only preventive intervention is an anti-Respiratory Syncytial Virus (RSV) monoclonal antibody (palivizumab, Synagis) administered as monthly intramuscular injections during the winter. Recommendations for palivizumab use have been published by the Canadian Paediatric Society (CPS) and other agencies. We sought to determine if there was interjurisdictional variation in eligibility for palivizumab across provinces and territories and in comparison to CPS recommendations, as well as the nature of this variation. Methods Eligibility criteria were obtained from personnel coordinating provincial and territorial programs and from public governmental websites. Results All 13 jurisdictions provided information about their palivizumab eligibility policies. No province or territory (PT) follows CPS guidelines exactly and substantial heterogeneity exists among jurisdictions. All PT jurisdictions provide prophylaxis in the first year of life to infants with hemodynamically significant congenital heart disease or chronic lung disease on ongoing therapy for those conditions, and to premature children in remote areas. In general, PTs had more liberal policies than the CPS, offering palivizumab to a wide range of children with conditions such as cystic fibrosis, Down syndrome or to moderately premature children with risk factors. Conclusions Substantial variation in PT criteria for RSV prevention exists in Canada, and no jurisdiction follows CPS criteria exactly. Variability in subnational policy may reflect access to human or material resources, varying interpretation of evidence for efficacy, variation in epidemiology, the effect of local pressures, or advocacy.